Business Context and Reporting Period
Cytosorbents Corp (CTS) filed a Form 8-K on October 2, 2025, reporting a regulatory event concerning its listing status on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial data point disclosed is the stock price performance triggering the notice: the common stock closed below $1.00 per share for 30 consecutive business days.
Material Changes
The material change is the receipt of a written notice from Nasdaq indicating non-compliance with Listing Rule 5550(a)(2) (Minimum Bid Price Requirement). This notice has no immediate effect on the listing or trading of the stock.
Outlook, Risks, and Management Commentary
- Compliance Timeline: The Company has 180 calendar days, until March 31, 2026, to regain compliance.
- Compliance Criteria: The closing bid price must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to the Compliance Date.
- Contingency: If compliance is not met by March 31, 2026, the Company may be eligible for an additional 180-day period if it presents an acceptable plan to Nasdaq.
- Risk: Management states there can be no assurance that the Company will regain compliance or meet other listing standards.
Investor Verification Checklist
- Verify the current closing bid price of CTSO relative to the $1.00 threshold.
- Monitor the Company's stock price for 10 consecutive days of trading at or above $1.00 to confirm compliance.
- Review future filings for any announced plans (e.g., reverse stock splits) intended to address the bid price deficiency.
- Check for any subsequent notices from Nasdaq regarding the extension of the compliance period or potential delisting.